TSVT

NASDAQ

2seventy bio Inc.

SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations

News25/Ratings12

2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts. 2seventy bio, Inc.(NasdaqGS:TSVT.V) operates independently of bluebird bio, Inc. as of November 4, 2021.

Latest news

25 items

335dSEC
SEC Form 15-12G filed by 2seventy bio Inc.
15-12G - 2seventy bio, Inc. (0001860782) (Filer)
343dINSIDER
Director Glickman Sarah Js returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
343dINSIDER
SEC Form 4 filed by Director Casdin Capital, Llc
4 - 2seventy bio, Inc. (0001860782) (Issuer)
343dINSIDER
Director Leschly Nick returned 335,964 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
343dINSIDER
Chief Financial Officer Eatwell Victoria returned 401,111 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
343dINSIDER
Chief Operating Officer Snow Jessica returned 247,230 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
343dINSIDER
Director Wei Lin returned 17,583 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
343dINSIDER
Director Maus Marcela V. returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
343dINSIDER
Director Newton Charles W. returned 17,092 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
343dINSIDER
Director Torres Denice returned 12,050 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
343dINSIDER
President and CEO Baird William D Iii returned 1,002,825 shares to the company, closing all direct ownership in the company (SEC Form 4)
4 - 2seventy bio, Inc. (0001860782) (Issuer)
345dSEC
SEC Form EFFECT filed by 2seventy bio Inc.
EFFECT - 2seventy bio, Inc. (0001860782) (Filer)
345dSEC
SEC Form POS AM filed by 2seventy bio Inc.
POS AM - 2seventy bio, Inc. (0001860782) (Filer)
345dSEC
SEC Form S-8 POS filed by 2seventy bio Inc.
S-8 POS - 2seventy bio, Inc. (0001860782) (Filer)
345dSEC
SEC Form S-8 POS filed by 2seventy bio Inc.
S-8 POS - 2seventy bio, Inc. (0001860782) (Filer)
345dSEC
SEC Form S-8 POS filed by 2seventy bio Inc.
S-8 POS - 2seventy bio, Inc. (0001860782) (Filer)
345dSEC
SEC Form S-8 POS filed by 2seventy bio Inc.
S-8 POS - 2seventy bio, Inc. (0001860782) (Filer)
345dSEC
2seventy bio Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Completion of Acquisition or Disposition of Assets, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits
8-K - 2seventy bio, Inc. (0001860782) (Filer)
345dSEC
SEC Form 25-NSE filed by 2seventy bio Inc.
25-NSE - 2seventy bio, Inc. (0001860782) (Subject)
345dSEC
Amendment: SEC Form SC 14D9/A filed by 2seventy bio Inc.
SC 14D9/A - 2seventy bio, Inc. (0001860782) (Subject)
345dSEC
Amendment: SEC Form SC TO-T/A filed by 2seventy bio Inc.
SC TO-T/A - 2seventy bio, Inc. (0001860782) (Subject)
351dSEC
SEC Form 10-Q filed by 2seventy bio Inc.
10-Q - 2seventy bio, Inc. (0001860782) (Filer)
351dSEC
2seventy bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - 2seventy bio, Inc. (0001860782) (Filer)
351dPR
2seventy bio Reports First Quarter Financial Results and Provides Update on Proposed Acquisition by Bristol Myers Squibb
Acquisition by Bristol Myers Squibb on track to close in the second quarter of 2025: HSR waiting period expired on May 2, 2025; tender offer expected to expire on May 13, 2025 Abecma generated $59 million U.S. commercial revenue in the first quarter of 2025 Ended quarter with approximately $173 million in cash, cash equivalents, and marketable securities 2seventy bio, Inc. (NASDAQ:TSVT), today reported financial results and recent highlights for the first quarter ended March 31, 2025. "We started 2seventy with a singular focus on harnessing the power of cell therapy to deliver more time for people living with cancer," said Chip Baird, chief executive officer, 2seventy bio. "Over the pas
352dSEC
Amendment: SEC Form SC TO-T/A filed by 2seventy bio Inc.
SC TO-T/A - 2seventy bio, Inc. (0001860782) (Subject)